Navigation Links
GW Pharmaceuticals to Report Q3 2013 Results and Host Conference Call on 5 August, 2013
Date:7/15/2013

LONDON, July 15, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 August 2013 its financial results for the third quarter ending 30 June, 2013. GW will also host a conference call the same day at 1:00 p.m. BST (8:00 a.m. EDT).

Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 21 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively, and at least two additional programs expected to enter Phase 1 and Phase 2 clinical trials in the next 12 months. For further information, please visit www.gwpharm.com.


'/>"/>
SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan 17, 2017 Research and ... Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), ... - Global Forecast to 2021" report to their offering. ... The global active ... 2021 from USD 157.95 Billion in 2016, growing at a CAGR ...
(Date:1/17/2017)... 17, 2017 Immune Pharmaceuticals (NASDAQ: ... today that it will hold a Satellite Symposium on February ... (ISAL) XVI in Munich, Germany . ... Efficacy of Immunotherapy for the maintenance of remission in ... 20 th , 2017 from 12:45 – 13:45 CET ...
(Date:1/17/2017)... PARSIPPANY, N.J. , Jan. 17, 2017 Interpace ... that provides clinically useful molecular diagnostic tests and pathology ... it has received a letter dated January 13, 2017 ... it has regained compliance with the requirement of the ... price of $1.00 per share. The letter ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... ... century approach to infusing high speed technology into the fabric of an entire ... the advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading ...
(Date:1/17/2017)... ... 17, 2017 , ... Surgeons from New York’s fastest growing ... on the latest breakthroughs in the prevention, diagnosis and treatment of the most ... eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD and Managing ...
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading ... a Principal in its IT Advisory Services practice . Rossi is the third ... market demand for strategic IT guidance grows, and the practice continues to expand.     , ...
(Date:1/17/2017)... York, NY (PRWEB) , ... January 17, 2017 ... ... Inc. Magazine’s fastest-growing private companies and ranked among the top US security companies ... Board of Directors. This announcement brings a year-long independent board nomination process ...
(Date:1/16/2017)... , ... January 17, 2017 , ... Recently, patients and ... Southwest Michigan, joined other volunteers and organizations in support of the annual Binder Park ... and families dressed up in colorful costumes of all designs coming out to enjoy ...
Breaking Medicine News(10 mins):